CN109843320A - 稳定表达il-10和胰岛素的遗传修饰的细菌 - Google Patents

稳定表达il-10和胰岛素的遗传修饰的细菌 Download PDF

Info

Publication number
CN109843320A
CN109843320A CN201780054190.7A CN201780054190A CN109843320A CN 109843320 A CN109843320 A CN 109843320A CN 201780054190 A CN201780054190 A CN 201780054190A CN 109843320 A CN109843320 A CN 109843320A
Authority
CN
China
Prior art keywords
lab
gene
nucleic acid
lactobacillus
exogenous nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780054190.7A
Other languages
English (en)
Chinese (zh)
Inventor
P·罗蒂尔斯
L·斯蒂德勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intrexon Actobiotics NV
Original Assignee
Intrexon Actobiotics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrexon Actobiotics NV filed Critical Intrexon Actobiotics NV
Priority to CN202410943767.1A priority Critical patent/CN118813511A/zh
Publication of CN109843320A publication Critical patent/CN109843320A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201780054190.7A 2016-09-02 2017-09-02 稳定表达il-10和胰岛素的遗传修饰的细菌 Pending CN109843320A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410943767.1A CN118813511A (zh) 2016-09-02 2017-09-02 稳定表达il-10和胰岛素的遗传修饰的细菌

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662383079P 2016-09-02 2016-09-02
US62/383,079 2016-09-02
PCT/IB2017/055287 WO2018042390A1 (en) 2016-09-02 2017-09-02 Genetically modified bacteria stably expressing il-10 and insulin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410943767.1A Division CN118813511A (zh) 2016-09-02 2017-09-02 稳定表达il-10和胰岛素的遗传修饰的细菌

Publications (1)

Publication Number Publication Date
CN109843320A true CN109843320A (zh) 2019-06-04

Family

ID=60120085

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780054190.7A Pending CN109843320A (zh) 2016-09-02 2017-09-02 稳定表达il-10和胰岛素的遗传修饰的细菌
CN202410943767.1A Withdrawn CN118813511A (zh) 2016-09-02 2017-09-02 稳定表达il-10和胰岛素的遗传修饰的细菌

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410943767.1A Withdrawn CN118813511A (zh) 2016-09-02 2017-09-02 稳定表达il-10和胰岛素的遗传修饰的细菌

Country Status (8)

Country Link
US (3) US10858663B2 (https=)
EP (1) EP3506932B1 (https=)
JP (3) JP7016865B2 (https=)
CN (2) CN109843320A (https=)
AU (1) AU2017319707B2 (https=)
CA (1) CA3035151A1 (https=)
RU (1) RU2768027C2 (https=)
WO (1) WO2018042390A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116726158A (zh) * 2023-04-24 2023-09-12 中国医学科学院医学生物学研究所 一种多表位1型糖尿病疫苗及其制备方法
WO2024146463A1 (zh) * 2023-01-03 2024-07-11 深圳先进技术研究院 分泌白介素-10的细菌

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7016865B2 (ja) * 2016-09-02 2022-03-03 イントレクソン・アクトバイオテイクス・エヌブイ Ｉｌ－１０およびインスリンを安定的に発現する遺伝子改変された細菌
CN109983028B (zh) 2016-09-13 2023-10-20 英特瑞克斯顿阿克图比奥帝克斯有限公司 黏膜黏附性微生物
EP4582440A3 (en) * 2018-12-21 2025-10-08 The Regents of the University of California Il-10-containing vaccines and uses thereof
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003064607A2 (en) * 2002-01-31 2003-08-07 Symbigene, Inc. Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions
CN101605900A (zh) * 2007-01-12 2009-12-16 阿克图杰尼斯公司 乳球菌启动子和其用途
CN101605559A (zh) * 2007-01-25 2009-12-16 阿克图杰尼斯公司 使用遗传修饰的乳杆菌通过抗原的粘膜递送治疗免疫疾病
US20140105863A1 (en) * 2011-06-01 2014-04-17 Actogenix N.V. Polycistronic expression system for bacteria
CN103917639A (zh) * 2011-09-23 2014-07-09 阿克托杰尼斯有限公司 经修饰的革兰氏阳性细菌及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB227835A (en) 1924-01-15 1925-04-09 Harry Odell Improvements in feeding mechanism for embossing and other printing presses
US4919918A (en) 1988-03-14 1990-04-24 Spectrum Consumer Products Co., Inc. Non-alcoholic mouthwash
US5972685A (en) 1988-07-21 1999-10-26 Iowa State University Research Foundation, Inc. Oral administration of coprostanol producing microorganisms to humans to decrease plasma cholesterol concentration
GB9126306D0 (en) 1991-12-11 1992-02-12 Unilever Plc Mouthwash compositions
JPH07504815A (ja) 1992-02-27 1995-06-01 マイクロバイアル　テクニクス　リミティド 乳酸菌における異種遺伝子の発現およびその発現産物
US5223285A (en) 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients
US5700782A (en) 1993-05-28 1997-12-23 Abbott Laboratories Enteral nutritional product
WO1996032486A1 (en) 1995-04-11 1996-10-17 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Method for the construction of vectors for lactic acid bacteria like lactobacillus such that the bacteria can efficiently express, secrete and display proteins at the surface
US5695746A (en) 1995-07-28 1997-12-09 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Liquid dentifrice with mouthwash fresh taste
WO1997026855A1 (en) 1996-01-24 1997-07-31 Warner-Lambert Company Peroxide/essential oils containing mouthwash compositions and two-part mouthwash systems
GB9611364D0 (en) 1996-05-31 1996-08-07 Smithkline Beecham Plc Composition
PT939613E (pt) 1996-09-18 2003-07-31 Erling Johansen Solucao sobressaturada para lavagem bucal contendo ioes calcio e fosfato
US5869118A (en) 1996-11-13 1999-02-09 Abbott Laboratories Gellan gum to improve physical stability of liquid nutritional products
US5897872A (en) 1997-11-12 1999-04-27 Picciano; Dante J. Iodine-containing nasal moisturizing saline solution
US6171611B1 (en) 1997-11-12 2001-01-09 Dante J. Picciano Iodine-containing nasal moisturizing saline and mouthwash solutions
JP5068401B2 (ja) 1998-09-28 2012-11-07 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップ Ｈｐｍｃカプセルを使用する腸及び結腸への送達
AU1071200A (en) 1998-10-19 2000-05-08 Biotech Australia Pty Limited Systems for oral delivery
WO2002090551A2 (en) 2001-05-03 2002-11-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Self-containing lactococcus strain
US20040076590A1 (en) 2002-07-08 2004-04-22 Wilkins Joe S. Antibacterial toothpaste and mouthwash formulations
WO2004056850A2 (en) * 2002-12-19 2004-07-08 Vib Vzw Mutant proteins showing increased secretion
AU2006319216B2 (en) 2005-11-29 2012-09-13 Intrexon Actobiotics Nv Induction of mucosal tolerance to antigens
BRPI0809448A2 (pt) * 2007-03-28 2014-09-09 Alimentary Health Ltd Cepas de bifidobacterium probióticas
JP5572972B2 (ja) * 2009-03-16 2014-08-20 Ｊｎｃ株式会社 インスリン分泌促進剤などの薬物のスクリーニング方法
WO2010124855A1 (en) 2009-04-30 2010-11-04 Actogenix Nv Cryoprotectants for freeze drying of lactic acid bacteria
WO2013041672A1 (en) * 2011-09-23 2013-03-28 Actogenix Nv Modified gram positive bacteria and uses thereof
JP7016865B2 (ja) * 2016-09-02 2022-03-03 イントレクソン・アクトバイオテイクス・エヌブイ Ｉｌ－１０およびインスリンを安定的に発現する遺伝子改変された細菌

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003064607A2 (en) * 2002-01-31 2003-08-07 Symbigene, Inc. Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions
US20040043003A1 (en) * 2002-01-31 2004-03-04 Wei Chen Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions
CN101605900A (zh) * 2007-01-12 2009-12-16 阿克图杰尼斯公司 乳球菌启动子和其用途
CN101605559A (zh) * 2007-01-25 2009-12-16 阿克图杰尼斯公司 使用遗传修饰的乳杆菌通过抗原的粘膜递送治疗免疫疾病
US20140105863A1 (en) * 2011-06-01 2014-04-17 Actogenix N.V. Polycistronic expression system for bacteria
CN103917639A (zh) * 2011-09-23 2014-07-09 阿克托杰尼斯有限公司 经修饰的革兰氏阳性细菌及其用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LOTHAR STEIDLER等: "Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10", NAT BIOTECHNOL, vol. 21, no. 7, pages 786 *
TATIANA TAKIISHI等: "Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice", 《JOURNAL OF CLINICAL INVESTIGATION》 *
TATIANA TAKIISHI等: "Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice", 《JOURNAL OF CLINICAL INVESTIGATION》, vol. 122, no. 5, 9 April 2012 (2012-04-09), pages 1718 - 1723 *
TATIANA TAKIISHI等: "Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice", JOURNAL OF CLINICAL INVESTIGATION, vol. 122, no. 5, pages 1718 - 1723 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024146463A1 (zh) * 2023-01-03 2024-07-11 深圳先进技术研究院 分泌白介素-10的细菌
CN116726158A (zh) * 2023-04-24 2023-09-12 中国医学科学院医学生物学研究所 一种多表位1型糖尿病疫苗及其制备方法

Also Published As

Publication number Publication date
JP2024047590A (ja) 2024-04-05
CN118813511A (zh) 2024-10-22
JP2019526262A (ja) 2019-09-19
US12359210B2 (en) 2025-07-15
EP3506932B1 (en) 2025-06-25
EP3506932A1 (en) 2019-07-10
JP2022061035A (ja) 2022-04-15
RU2019104948A (ru) 2020-10-02
US11549118B2 (en) 2023-01-10
US20190292551A1 (en) 2019-09-26
RU2768027C2 (ru) 2022-03-23
RU2019104948A3 (https=) 2020-12-23
CA3035151A1 (en) 2018-03-08
AU2017319707B2 (en) 2023-11-09
WO2018042390A1 (en) 2018-03-08
AU2017319707A1 (en) 2019-03-07
US20210180072A1 (en) 2021-06-17
JP7016865B2 (ja) 2022-03-03
US10858663B2 (en) 2020-12-08
US20230348918A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
CN109843320A (zh) 稳定表达il-10和胰岛素的遗传修饰的细菌
AU2021202600B2 (en) Compositions and methods for the treatment of type 1 diabetes
US12252516B2 (en) Mucoadhesive microorganism
KR20150065170A (ko) 관심있는 화합물을 발현하는 형질전환된 박테리아를 포함하는 국소 조성물
Liu Genomic and metagenomic studies of the gut and skin microbiome with probiotic applications
HK1262225B (en) Compositions and methods for the treatment of type 1 diabetes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190604